Cargando…
A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity
INTRODUCTION: There is an unmet clinical need for biomarkers to identify breast cancer patients at an increased risk of developing brain metastases. The objective is to identify gene signatures and biological pathways associated with human epidermal growth factor receptor 2-positive (HER2+) brain me...
Autores principales: | McMullin, Ryan P, Wittner, Ben S, Yang, Chuanwei, Denton-Schneider, Benjamin R, Hicks, Daniel, Singavarapu, Raj, Moulis, Sharon, Lee, Jeongeun, Akbari, Mohammad R, Narod, Steven A, Aldape, Kenneth D, Steeg, Patricia S, Ramaswamy, Sridhar, Sgroi, Dennis C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4053087/ https://www.ncbi.nlm.nih.gov/pubmed/24625110 http://dx.doi.org/10.1186/bcr3625 |
Ejemplares similares
-
Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors
por: Faraoni, Isabella, et al.
Publicado: (2018) -
Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA Mutations
por: Xu, Qin, et al.
Publicado: (2021) -
Nanoparticle Formulations of Poly (ADP-ribose) Polymerase Inhibitors for Cancer Therapy
por: Singh, Bijay, et al.
Publicado: (2020) -
RNA regulation by Poly(ADP-ribose) polymerases
por: Bock, Florian J., et al.
Publicado: (2015) -
Mitotic functions of poly(ADP-ribose) polymerases
por: Slade, Dea
Publicado: (2019)